{"symbol":"REGN","fiscalQuarter":"Q1-2018","reportDate":"2018-05-03","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2018","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.26%","keyNumbers":[{"metric":"EPS","actual":"$4.70","expected":"N/A","surprise":"+0.42%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","While we did not provide revenue guidance, we remain focused on our pipeline."],"summary":"Management expressed satisfaction with the EPS results, indicating a strong performance. However, they did not provide specific guidance for future revenue."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a positive surprise in EPS, which reflects the company's profitability. However, the stock fell by 1.26%, likely due to the absence of revenue guidance and uncertainty about future performance. Investors may be cautious as they await more details on revenue expectations.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2018 earnings: EPS beat by 0.42%. Stock down 1.26%. Full breakdown."}}